Decitabine has been shown to increase tumor-infiltrating T cells and to upregulate the expression of immune checkpoints, such PD-1 and PD-L1, ameliorating the effectiveness of immune checkpoint blockade in colorectal cancer [43–45] and PDAC [46]. The gene discussed is RPL17; the disease is colorectal cancer.